<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01287390</url>
  </required_header>
  <id_info>
    <org_study_id>2011/012</org_study_id>
    <nct_id>NCT01287390</nct_id>
  </id_info>
  <brief_title>Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck</brief_title>
  <official_title>Adaptive, Image-guided, Intensity-modulated Radiotherapy for Head and Neck Cancer in the Reduced Volumes of Elective Neck: a Multicenter, Two-arm, Randomized Phase II Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Ghent</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Ghent</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe acute and late dysphagia is now considered as a dose-limiting toxicity of&#xD;
      radio(chemo)therapy for head and neck cancer that significantly affects patients' quality of&#xD;
      life. We propose to preserve swallowing function by:&#xD;
&#xD;
        -  adapting (individualizing) treatment (intensity-modulated radiotherapy: IMRT) to&#xD;
           per-treatment changes occurring in the tumor and surrounding organs and tissues;&#xD;
&#xD;
        -  reducing the volumes of elective neck, that may result in significant decrease of severe&#xD;
           acute and late dysphagia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of acute and late treatment-induced dysphagia</measure>
    <time_frame>after 1 year</time_frame>
    <description>Reduction of the rates of acute and late treatment-induced dysphagia with experimental treatment as compared to standard treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>acute treatment-induced toxicity</measure>
    <time_frame>weekly during treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late treatment-induced toxicity</measure>
    <time_frame>after 1, 3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor response: imaging</measure>
    <time_frame>after 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tumor response: clinical examination</measure>
    <time_frame>after 1, 3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local, regional and distant control: imaging</measure>
    <time_frame>after 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local, regional and distant control: clinical examination</measure>
    <time_frame>after 1,3, 6, 9 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local, regional and distant control: biopsy</measure>
    <time_frame>from 3 months on</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Primary Non-operated Squamous Cell Carcinoma of Oral Cavity</condition>
  <condition>Primary Non-operated Squamous Cell Carcinoma of Oropharynx</condition>
  <condition>Primary Non-operated Squamous Cell Carcinoma of Hypopharynx</condition>
  <condition>Primary Non-operated Squamous Cell Carcinoma of Larynx</condition>
  <arm_group>
    <arm_group_label>standard radiotherapy treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These patients receive the normal standard treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>adaptive radiotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>These patients receive the adaptive image-guided intensity-modulated radiotherapy (IMRT) for head and neck cancer.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>video fluoroscopy</intervention_name>
    <description>video fluoroscopy of swallowing function at baseline, 6 months and 12 months follow-up</description>
    <arm_group_label>adaptive radiotherapy</arm_group_label>
    <arm_group_label>standard radiotherapy treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>extra imaging</intervention_name>
    <description>For tumor response, 2 extra CT or Fludeoxyglucose (18F)-Positron Emission Tomography (PET)/Computed Tomography (CT), and/or Magnetic Resonance Imaging (MRI) will be performed.</description>
    <arm_group_label>adaptive radiotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>scoring acute toxicity</intervention_name>
    <description>Acute toxicity scoring, based on Common Toxicity criteria (CTC) version 2.</description>
    <arm_group_label>adaptive radiotherapy</arm_group_label>
    <arm_group_label>standard radiotherapy treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>scoring of late toxicity</intervention_name>
    <description>Scoring of late toxicity with the 'late effects in normal tissues subjective, objective, management and analytic'(LENT-SOMA) scale.</description>
    <arm_group_label>adaptive radiotherapy</arm_group_label>
    <arm_group_label>standard radiotherapy treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>scoring quality of life (QOL)</intervention_name>
    <description>Quality of life is scored with the Quality of Life Questionnaire of the 'European Organisation for Research and Treatment of Cancer' (EORTC QOL-C30) and the Head and Neck Cancer Specific Quality of Life Questionnaire (QLQ-H&amp;N 35).</description>
    <arm_group_label>adaptive radiotherapy</arm_group_label>
    <arm_group_label>standard radiotherapy treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed squamous cell carcinoma of the oral cavity, oropharynx,&#xD;
             hypopharynx and larynx.&#xD;
&#xD;
          -  Primary non-resected tumor and/or patients refused surgery&#xD;
&#xD;
          -  Stage T1-4, N0-3; for cancer of the glottis T3-4 or T any N1-3&#xD;
&#xD;
          -  Decision of curative radiotherapy or radiochemotherapy made by a Multidisciplinary&#xD;
             Group of Head and Neck Tumors at UZ Gent and UZ Gasthuisberg Leuven&#xD;
&#xD;
          -  Karnofsky performance status &gt;= 70 %&#xD;
&#xD;
          -  Age &gt;= 18 years old&#xD;
&#xD;
          -  Informed consent obtained, signed and dated before specific protocol procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment combined with brachytherapy&#xD;
&#xD;
          -  Prior irradiation to the head and neck region&#xD;
&#xD;
          -  Surgery of the primary tumor except lymph node dissection prior to radiotherapy&#xD;
&#xD;
          -  induction chemotherapy&#xD;
&#xD;
          -  history of prior malignancies, except for cured non-melanoma skin cancer, curatively&#xD;
             treated in-situ carcinoma of the cervix or other cancer curatively treated and with no&#xD;
             evidence of disease at least 5 years&#xD;
&#xD;
          -  Distant metastases&#xD;
&#xD;
          -  Creatinine clearance (Cockroft-Gault) =&lt; 60 milliliter/minute before treatment or&#xD;
             creatinine value &gt; 1,3 milligram/deciliter&#xD;
&#xD;
          -  Known allergy to the CT-contrast agents&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Mental condition rendering the patient unable to understand the nature, scope and&#xD;
             possible consequences of the study&#xD;
&#xD;
          -  Patient unlikely to comply with protocol, i.e. uncooperative attitude, inability to&#xD;
             return for follow-up visits and unlikely to complete the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wilfried De Neve, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Ghent</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Ghent</name>
      <address>
        <city>Ghent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://www.uzgent.be</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2016</verification_date>
  <study_first_submitted>January 26, 2011</study_first_submitted>
  <study_first_submitted_qc>January 31, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2011</study_first_posted>
  <last_update_submitted>January 26, 2016</last_update_submitted>
  <last_update_submitted_qc>January 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>squamous cell carcinoma</keyword>
  <keyword>oral cavity</keyword>
  <keyword>oropharynx</keyword>
  <keyword>hypopharynx</keyword>
  <keyword>larynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

